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Abstract: Soy isoflavones have been documented as dietary nutrients broadly classified as 
“natural agents” which plays important roles in reducing the incidence of hormone-related 
cancers in Asian countries, and have shown inhibitory effects on cancer development and 
progression in vitro and in vivo, suggesting the cancer preventive or therapeutic activity of 
soy isoflavones against cancers. Emerging experimental evidence shows that isoflavones 
could induce cancer cell death by regulating multiple cellular signaling pathways including 
Akt, NF-κB, MAPK, Wnt, androgen receptor (AR), p53 and Notch signaling, all of which 
have been found to be deregulated in cancer cells. Therefore, homeostatic regulation of 
these important cellular signaling pathways by isoflavones could be useful for the 
activation of cell death signaling, which could result in the induction of apoptosis of both 
pre-cancerous and/or cancerous cells without affecting normal cells. In this article, we have 
attempted to summarize the current state-of-our-knowledge regarding the induction of 
cancer cell death pathways by isoflavones, which is believed to be mediated through the 
regulation of multiple cellular signaling pathways. The knowledge gained from this article 
will provide a comprehensive view on the molecular mechanism(s) by which soy 
isoflavones may exert their effects on the prevention of tumor progression and/or treatment 
of human malignancies, which would also aid in stimulating further in-depth mechanistic 
research and foster the initiation of novel clinical trials. 
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1. Introduction 
Cancer cells are known to exhibit deregulations in multiple signaling pathways, leading to 
uncontrolled cell proliferation and acquired anti-apoptosis features. Apoptosis also known as 
programmed cell death, an important physiological process, which occurs in cells during development 
and normal cellular processes. It contains sequential responses to biochemical or physical signals to 
maintain cellular homeostasis because the damaged and useless cells must die through apoptotic 
process for their elimination. It has been known that cells altered beyond repair by normal mechanisms 
or cells that have completed their biological function proceed to the apoptosis process [1]. Apoptosis is 
induced by several cellular signals which alter mitochondrial permeability, leading to a cascade of 
events such as the release of apoptosis activators from mitochondria, which leads to the activation of 
caspases (cysteinyl-aspartate-specific proteinases), a family of intracellular cysteine proteases causing 
apoptotic cell death [2–4]. The activation of caspases then targets their downstream molecules [2–4]. 
Poly-ADP-Ribose-Polymerase (PARP) is one of the targets of caspases and specifically binds at DNA 
strand breaks. The activated caspases cleave PARP to two fragments during early stages of apoptosis; 
therefore, the cleavage of PARP is an early marker of apoptosis [5,6]. Other important genes involved 
in the apoptotic processes include Bcl-2, Bcl-XL, Bax, p53, etc. [7–9]. Among them, Bcl-2 and Bax 
are known to play critical roles in apoptosis, and most interestingly the ratio of Bcl-2 and Bax reflects 
the status of apoptosis. 
During the apoptotic process, another important cellular response is the activation of endogenous 
Ca
2+ and Mg
2+-dependent nuclear endonuclease [10]. In human chromosome, histone and DNA   
strand tightly bind to form nucleosomal units, and each unit includes ~180–200 bp DNA and histone 
protein. When apoptosis occurs, the activated endonuclease selectively cleaves DNA at sites located 
between nucleosomal units, generating typical ~180–200 bp × n DNA fragments with histone and 
eventually leading to changes in the morphological features [11]. These features include chromatin 
aggregation, nuclear and cytoplasmic condensation, partition of cytoplasm and nucleus into membrane 
bound-vesicles that are known as apoptotic bodies. In vivo, these apoptotic bodies are rapidly recognized 
and phagocytosed by either macrophages or adjacent epithelial cells. In this way, the unwanted or 
damaged cells are eliminated to maintain the normal physiological homeostasis. However, if the cellular 
signals for initiating apoptosis are lost, a variety of malignant disorders may result. Development  
and differentiation of normal tissue are controlled by a balance between cell proliferation and 
apoptosis, and defects in such balance leads to the development of cancers because of uncontrolled cell 
proliferation and reduced apoptotic cell death [12,13]. In cancers, un-repaired damaged cells survive and 
grow, resulting in uncontrolled cancer growth, invasion and metastasis. It is now generally accepted 
that defective apoptosis mechanism plays important roles in carcinogenesis and cancer progression.  
It is important to note that the activators and inhibitors of apoptosis are also the molecules distributed 
in various cellular signaling pathways. Cellular signaling is a complex signal communication network 
which controls biological activities of cells and coordinates cellular function including apoptosis. The Nutrients 2011, 3  
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signaling cascades are typically composed of three-dimensional pathways of proteins which regulate 
each other within a specific sub-cellular location in the cells [14]. Because of the complex transduction 
of cell signal, cancer cells always exhibit the alterations in multiple cellular signaling pathways. It is 
known that several important cellular signaling pathways including NF-κB, Akt, MAPK, Wnt, Notch, 
p53, AR, etc., control apoptosis and cell proliferation. Importantly, all of these signaling pathways 
have been found malfunctioning in cancer cells, resulting in defective apoptosis, increased tumor 
growth, invasion, and metastasis [15–19]. Moreover, the ability of cancer cells to evade apoptosis also 
plays a critical role in de novo (intrinsic) and acquired (extrinsic) resistance to conventional 
therapeutics [13,20]. Therefore, it is important to design a strategy that could simultaneously target 
multiple cellular signaling pathways, which will lead to increased apoptotic cell death and enhanced 
cell growth inhibition in order to eliminate cancer cells. 
Recently, dietary compounds have received much attention in the field of cancer prevention and 
therapy, primarily because epidemiological studies have shown that the consumption of fruits, soybean 
and vegetables is associated with reduced risk of several types of cancers [21–23]. The dietary 
compounds including isoflavone-genistein, indole-3-carbinol (I3C), 3,3′-diindolylmethane (DIM), 
curcumin, (−)-epigallocatechin-3-gallate (EGCG), resveratrol, lycopene, etc., have been recognized as 
cancer chemopreventive agents because of their anti-carcinogenic activity [24,25]. Moreover, the   
in vitro and in vivo studies have demonstrated that these dietary compounds have inhibitory effects on 
various human and animal cancers [26–29]. Furthermore, experimental studies have demonstrated that 
these dietary compounds can enhance the anti-tumor activity of chemotherapeutic agents by regulation 
of cellular signal transduction pathways, resulting in the induction of apoptotic cell death. Among 
these compounds, isoflavones show their strong effects on apoptosis pathways. Soy isoflavones such 
as genistein, daidzein, and glycitein are mainly derived from soybean. Isoflavone-genistein has been 
found to induce apoptotic cell death in vivo and in vitro [30,31]. Emerging evidence from increasing 
number of investigations on isoflavones has shown that isoflavones exert their pleiotropic effects on 
cancer cells through targeting multiple cellular signaling pathways including NF-κB, Akt, MAPK, 
Wnt, Notch, p53, and AR pathways, suggesting that isoflavone could be useful either alone or in 
combination with conventional therapeutics for the prevention of tumor progression and/or treatment 
of human malignancies. 
2. Deregulation of Cellular Signaling and Apoptosis Pathway in Cancer Cells 
In cancer cells, altered proteins produced due to mutations, other defects, or amplifications of genes, 
impact cellular signal communication which controls apoptotic cell death. NF-κB, Akt, MAPK, Wnt, 
Notch, p53, and AR pathways are commonly deregulated in various cancers as discussed in-depth in 
the following sections. 
Nuclear factor-κB (NF-κB) signaling pathway plays important roles in the control of cell growth, 
apoptosis, inflammation, stress response, and many other physiological processes [16,32,33]. Several 
important molecules such as NF-κB, IκB, and IKK in the NF-κB signaling pathway regulate apoptotic 
signal transduction; however, NF-κB is the key protein in the pathway and has been described as a 
major culprit and a therapeutic target in cancer [34,35]. The activation of NF-κB is frequently observed 
in various cancer cells. The constitutive activation of NF-κB observed in cancer cells is likely due to Nutrients 2011, 3  
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the involvement of multiple other signal transduction pathways such as tyrosine kinase, NIK, and Akt 
pathways. It is known that NF-κB is a key modulator of apoptosis in a variety of cell types. Activation of 
NF-κB inhibits apoptosis while inhibition of NF-κB sensitizes human cancer cells to apoptosis [36,37], 
suggesting that NF-κB signaling plays important roles in apoptotic pathway (Figure 1). 
Figure 1. Cellular signaling pathways involved in the induction of apoptosis by isoflavone. 
 
Experimental studies have demonstrated the crosstalk between NF-κB and Akt signaling [38,39]. 
Akt signaling pathway also plays critical roles in cell survival regulation and is frequently activated in 
various cancers [40,41]. Akt is activated by cellular survival signals, leading to phosphorylation at 
Thr308 and Ser473 [42]. Activated Akt functions to promote cell survival by inhibiting apoptosis 
through inactivation of several pro-apoptotic factors including Bad, Forkhead transcription factors, and 
caspase-9 (Figure 1) [43–45]. Studies have also shown that Akt regulates the NF-κB pathway   
via phosphorylation and activation of molecules in the NF-κB signaling pathway [46,47], leading to 
the inhibition of apoptosis. Therefore, Akt is another attractive target for cancer prevention or 
treatment [48] because inactivation of Akt signaling could revert anti-apoptotic status in cancer cells 
via inhibition of pro-apoptotic factor and NF-κB. 
MAPK signaling is another signaling pathway which has received increasing attention as a target 
for cancer prevention and treatment. MAPK signaling includes a three-tiered kinase core where 
MAP3K activates MAP2K that activates MAPKs (ERK, JNK, and p38), leading to the activation of 
NF-κB, cell growth, and cell survival [49,50]. It has been reported that MAPK is activated in various 
cancer and that the activation of MAPK is also linked to cancer progression including angiogenesis, 
invasion, and metastasis [51]. The reported roles of MAPK signaling in apoptotic cell death are 
controversial. It has been reported that blocking the MEK/ERK signaling using the small-molecule 
MAPK inhibitors significantly enhances arsenic trioxide (ATO)-induced apoptosis in human myeloma Nutrients 2011, 3  
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cell lines [52]. Further studies showed that the inhibition of both MAPK and NF-κB signaling is 
necessary for rapid apoptosis in macrophages [53]. However, other reports also showed that activation 
of p38 MAPK was required for Bax translocation to mitochondria, cytochrome c release and apoptosis 
induced by UVB irradiation in human keratinocytes [54] and that protein kinase C induced apoptosis 
in LNCaP prostate cancer cells was mediated through the activation of p38 MAPK and inhibition of 
Akt pathway [55]. Therefore, further investigations are needed to resolve some existing controversies 
on the role of MAPK signaling in apoptosis pathway. 
Recent evidence has demonstrated that Wnt signaling plays important roles in cancer development 
and progression. Wnt signaling critically participates in the embryonic developmental processes 
including cell proliferation, differentiation, apoptosis and epithelial-mesenchymal interactions [56]. The 
aberrant activation of the canonical Wnt/β-catenin signaling is one of the most frequent signaling 
abnormalities known in human malignancy. In human cancers, activated Wnt signal promotes β-catenin 
accumulation in the nucleus, leading to the transcriptional activation of specific target genes which 
promote cancer progression (Figure 1) [57,58]. The aberrant expression of Wnt ligand and Wnt binding 
proteins and the activation of the Wnt signaling have been found in a variety of human tumors [59]. 
Experimental studies also showed that activation of Wnt signaling inhibited apoptosis in cancer cells. It 
has been found that Wnt signaling inhibits FOXO3a-induced transcription and apoptosis in colon 
cancer [60] and that Wnt proteins prevents apoptosis of osteoblasts through β-catenin, Src/ERK, and 
Akt signaling pathways [61]. Moreover, studies have shown that inactivation of Wnt signaling could 
induce apoptosis in colon cancer and melanoma [62,63]. Therefore, inhibition of aberrant Wnt activity 
in cancer cells could provide an opportunity for cancer treatment [64,65]. 
Similar to Wnt signaling, Notch signaling also participates in the embryonic developmental 
processes. Proper functioning of Notch signaling is required for normal development during early life. 
It has been found that Notch signaling plays critical roles in the regulation and maintenance of stem 
cells. Importantly, growing evidence demonstrates that deregulation of Notch signaling could lead to 
the development and progression of various cancers [66,67]. Up-regulation of Notch receptors and 
their ligands has been observed in lymphomas, cervical, lung, colon, head and neck, renal, and 
pancreatic cancers [66,68,69]. In cancer cells, Notch signaling is abnormally activated, leading to 
decreased apoptosis, increased proliferation of cancer cells, and induced Epithelial-to-Mesenchymal 
Transition (EMT), a process that is reminiscent of cancer stem-like cell characteristics (Figure 1). We 
and other investigators have found that Notch activation could induce pro-apoptosis molecules by 
activation of Akt or NF-κB signaling or by causing interference with XIAP ubiquitination and 
degradation [69–72]. Thus, the inhibition of Notch signaling could induce apoptosis and could also 
enhance sensitivity of cancer cells to conventional chemotherapeutics [73,74]. Therefore, Notch 
signaling pathway is now believed to be an important target for cancer therapy. However, few reports 
showed that Notch signaling could be a potent inducer of growth arrest and apoptosis [75,76], suggesting 
that the Notch signaling could be context-dependent, and thus further in-depth investigations are 
needed to address the existing controversies on the role of Notch as a target for cancer therapy. 
The p53 gene is a well-known transcription factor and tumor suppressor, which critically participates 
in many cellular processes including apoptosis, cell signal transduction, cellular response to   
DNA-damage, genomic stability, and cell cycle control (Figure 1). Wild-type p53 functions as a tumor 
suppressor and activates the transcription of its downstream genes such as p21
WAF1 and Bax to induce Nutrients 2011, 3  
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apoptosis and inhibit proliferation of DNA damaged cells or cancer cells. Importantly, the mutations and 
the inactivation of p53 have been found in various cancers and the status of p53 in cancer cells 
determines the cellular response to chemotherapy [77], suggesting that normalization of wild-type p53 
function could be a novel approach for the treatment of cancer.  
Androgen receptor (AR) is a ligand-activated transcription factor of the nuclear receptor 
superfamily that plays a critical role in male physiology and pathology, and also beginning to be 
realized for many functions in female as well. It has been well accepted that AR signaling contributes 
to carcinogenesis and cancer progression through regulating transcription of androgen-responsive 
genes (Figure 1) [78]. The deregulated AR signaling is commonly observed in cancer cells, especially 
prostate cancer cells. It is known that androgen and AR are involved in all stages of prostate cancers 
including initiation, progression, and treatment resistance [79], suggesting that AR signaling contributes 
to anti-apoptotic mechanism. Moreover, one of the androgen-responsive genes, prostate specific antigen 
(PSA), is a clinically important marker that is routinely used for diagnosis, monitor treatment response, 
prognosis and disease progression in patients diagnosed with prostate cancer [80,81]. Furthermore, 
during the progression of prostate cancer from androgen sensitive status to castrate resistant prostate 
cancer, the majority of prostate cancer cells still expresses AR, suggesting that AR signaling plays a 
critical role in the development and progression of prostate cancer [82]. Therefore, AR signaling has 
long been recognized as a main target for prostate cancer prevention and treatment. AR could also 
exhibit pro- or anti-apoptosis activity in different cellular situation. Androgen and AR could promote 
Bax-mediated apoptosis [83]; however, down-regulation of AR by synthetic or natural agents could 
also induce apoptosis and inhibit cancer cell proliferation [84,85]. These results clearly suggest that the 
AR signaling pathway is a complex signaling network, and thus further in-depth research in this area is 
an active area of investigation not only for prostate cancer but also for breast and other cancers. 
3. Regulation of Cellular Signaling to Induce Apoptosis by Isoflavone  
The cellular signaling is a complex signal network with positive or negative feedback loops and 
also regulated by compensatory mechanism. It is important to note that the apoptosis pathway is 
regulated by multiple cellular signaling. In cancer cells, the deregulations of multi-signaling and 
subsequent defective apoptosis often exist; therefore, targeting multiple signaling to induce apoptotic 
cell death by natural compound isoflavone could open a new avenue for cancer prevention and therapy 
as detailed in the following sections. 
Isoflavones are mainly found in members of the Leguminosae family. Foods such as soy, lentil, 
bean, and chickpea are sources of isoflavones; however, soybean is the food that contains abundant 
amounts of isoflavones. Several epidemiological studies have shown that soy could have protective 
effects against prostate and other cancers [86,87]. The mostly investigated isoflavone is genistein. 
Experimental studies have revealed that isoflavone, particularly genistein, exerts its antioxidant effects 
on human cells. Isoflavone genistein protects cells against reactive oxygen species by scavenging free 
radicals and reducing the expression of stress-response related genes. Isoflavone genistein is also a 
well known tyrosine kinase inhibitor. We and other investigators have found that isoflavone genistein 
exerts its significant effects on the induction of apoptosis in several different types of cancers including 
lymphoma, leukemia, breast, prostate, lung, head and neck, and pancreatic cancers [88–96]. We also Nutrients 2011, 3  
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found that isoflavone genistein treatment increased the expression of Bax and p21, decreased the 
expression of Bcl-2 and BclXL, and activated PARP and caspases, leading to the induction of apoptotic 
cell death [89–92,95,96]. Moreover, isoflavone has been well known to induce apoptosis through the 
regulation of several important cellular signaling pathways as detailed in the following sections. 
3.1. Isoflavone Induces Apoptosis through the Regulation of NF-κB Signaling 
It is well known that NF-κB inhibits apoptosis. Therefore, we examined the status of NF-κB activity 
in isoflavone genistein treated breast, prostate, lung, and pancreatic cancer cells by electrophoresis 
mobility shift assay (EMSA) during our earlier studies [91–93,95,97]. We found that isoflavone 
genistein significantly inhibited the DNA-binding activity of NF-κB in various cancer cells. 
Furthermore, isoflavone genistein pre-treatment abrogated the activation of NF-κB stimulated by H2O2 
or TNF-α. By immunochemistry and confocal microscopic analysis, we found that isoflavone, 
genistein inhibited the translocation of NF-κB to the nucleus, suggesting that isoflavone genistein may 
reduce the NF-κB binding to its target DNA and thereby inhibiting the transcription of its target genes 
such as Bcl-2, one of the important regulators of apoptosis. Recent studies have also shown that the 
induction of apoptosis by isoflavone, genistein and biochanin-A was mediated through both NF-κB 
dependent and independent pathways [98,99], suggesting the complexities of the biological activity  
of isoflavones. 
To investigate the in vivo effects of isoflavone genistein on NF-κB signaling, we conducted in vivo 
study [100] where we found that when human volunteers received 50 mg of soy isoflavone 
supplements Novasoy™ (containing genistein, daidzein, and glycitein at a 1.3:1:0.3 ratio) twice daily 
for three weeks, TNF-α treatment ex-vivo failed to activate NF-κB activity in lymphocytes harvested 
from these volunteers, while lymphocytes from these volunteers collected prior to soy isoflavone 
intervention showed activation of NF-κB DNA binding activity upon TNF-α treatment ex-vivo. These 
results have demonstrated that soy isoflavone supplementation has a protective effect against TNF-α 
induced NF-κB activation in humans, suggesting that soy isoflavone could exert its cancer 
chemopreventive activity through the inhibition of NF-κB signaling and induction of apoptosis, which 
is required for elimination of damaged or pre-cancerous cells in order to maintain normal homeostasis 
(Figure 1).  
More importantly, we have conducted additional in vitro and in vivo studies to investigate whether 
isoflavone could enhance the anti-tumor and pro-apoptotic activities of chemotherapeutic agents. We 
pre-treated cancer cells or mice having cancers with isoflavone genistein and subsequently administrated 
conventional chemotherapeutic agents. We found that isoflavone genistein could increase apoptosis and 
enhance the anti-tumor activity of chemotherapeutic agents via the down-regulation of NF-κB 
signaling [93], suggesting the potential therapeutic effects of isoflavone in cancer treatment. Other 
investigators have also reported similar observations [101,102]. Considering the non-toxic nature and 
the potent activity on the induction of apoptosis, isoflavone-genistein could be useful in combination 
with conventional chemotherapeutic agents for achieving better treatment outcome of patients 
diagnosed with cancers. Further studies have shown that isoflavone could also enhance the effects of 
radiation therapy in pre-clinical models [103,104]. Interestingly, clinical study has shown that 
isoflavone could protect human prostate cancer patients from adverse side effects of traditional Nutrients 2011, 3  
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radiation therapy [105], suggesting the clinical significance of isoflavones. Thus, we believe that these 
results will help to initiate additional clinical trials using isoflavones for cancer prevention and/or 
treatment in the future. 
3.2. Isoflavone Induces Apoptosis through the Regulation of Akt Signaling 
Isoflavone genistein-induced apoptosis could also be regulated by Akt signaling, another signaling 
pathway involved in anti-apoptosis. To address this issue, we have conducted experiments to 
investigate the relationship between apoptosis, NF-κB, and Akt signaling [91]. By kinase activity assay 
and Western blot analysis, we found that isoflavone genistein did not alter the level of total Akt 
protein; however, the phosphorylated Akt protein at Ser473 and the Akt kinase activity were decreased 
after isoflavone genistein treatment. Isoflavone genistein pre-treatment also abrogated the activation of 
Akt by EGF. To further explore the inhibitory mechanism of isoflavone genistein on Akt and NF-κB 
pathways, we conducted gene transfection experiment, luciferase assay, and EMSA. By conducting these 
experiments, we have demonstrated that isoflavone genistein could exert its inhibitory effects on NF-κB 
pathway through Akt pathway. Furthermore, isoflavone genistein significantly induced apoptosis under 
the above experimental conditions. We also observed similar results in MDA-MB-231 breast cancer  
cells [97]. Therefore, the down-regulation of NF-κB and Akt signaling pathways by isoflavone genistein 
may be one of the molecular mechanisms by which isoflavone genistein induces apoptosis. 
It is well known that activated Akt also inhibits apoptosis through the inhibition of GSK-3β and 
FOXO3a. We found that isoflavone genistein could inhibit the phosphorylation of Akt and FOXO3a, 
and up-regulated the expression of GSK-3β [94]. Isoflavone genistein also abrogated the 
phosphorylation of Akt and FOXO3a stimulated by IGF-1. Moreover, using four different apoptosis 
assays, we observed that isoflavone is an active agent to induce apoptosis, further abrogates the 
inhibition of apoptosis by IGF-1 treatment [94]. Other investigators recently reported similar findings 
showing that isoflavone genistein could induce apoptotic cell death through the regulation of Akt,  
NF-κB, and p21
WAF1 [106,107]. All these results suggest that the regulation of Akt pathway by 
isoflavone genistein contributes to the induction of apoptosis (Figure 1). 
3.3. Isoflavone Induces Apoptosis through the Regulation of MAPK Signaling 
Isoflavone genistein has been found to inhibit the molecules in the MAPK pathway, leading to the 
induction of apoptosis. It has been reported that genistein could block the activation of p38 MAPK by 
TGF-β while p38 MAPK was necessary for TGF-β-mediated induction of MMP-2 and cell invasion in 
prostate cancer [108]. Therefore, genistein could inhibit cancer cell invasion and metastasis by blocking 
the activation of p38 MAPK. In another report, genistein treatment also triggered the inhibition of p38 
MAPK activation in human hepatocellular carcinoma Hep3B cells [109]. Over-expression of p38 MAPK 
protected against apoptosis induced by combination treatment with genistein and TRAIL, suggesting  
that the p38 MAPK act as a key regulator of apoptosis in response to treatment with a combination  
of genistein and TRAIL [109]. In addition, synergistic anti-leukemia effect of genistein and 
chemotherapeutics in mouse xenograft model was found to be mediated through MAPK signaling [110]. 
Gene-expression profiling experiments revealed that MAPK signaling was one of the most affected 
biological pathways. MAPK kinase 4 was significantly down-regulated by genistein [110]. However, Nutrients 2011, 3  
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there are some controversial reports which showed that genistein potentiated apoptosis induced   
by arsenic trioxide in U937 human leukemia cells was regulated by ROS generation and p38   
MAPK activation [111,112], suggesting that further in-depth investigations are needed to address   
these controversies. 
3.4. Isoflavone Induces Apoptosis through the Regulation of Wnt Signaling 
It has been known that Wnt signaling interacts with Akt signaling, promoting cancer cell proliferation 
and preventing cancer cells from apoptosis. We have reported that isoflavone up-regulated the expression 
of GSK-3β, enhanced GSK-3β binding to β-catenin, increased the phosphorylation of β-catenin, and 
induced apoptotic cell death, suggesting that isoflavone could inactivate Wnt signaling to induce 
apoptosis and inhibit prostate cancer cell growth [94]. Other investigators have also shown that 
isoflavone genistein decreased basal and Wnt-1-induced growth, and also inhibited the expression   
of Wnt-1 targets, c-Myc and Cyclin D1, [113], and that isoflavone down-regulated the expression of 
Wnt-5a [114] and Wnt-7a [115]. Animal experiments coupled with microarray gene expression 
analysis also demonstrated that isoflavone genistein down-regulated Wnt signaling in the tumor tissues 
of animals treated with isoflavone genistein [114]. Furthermore, the gene expression profiles showed 
decreased expression of Wnt target genes such as Cyclin D1, which is also a regulator of apoptosis, in 
mammary ductal epithelium of the animals treated with isoflavone genistein [114]. These findings 
suggest that isoflavone genistein could induce apoptosis and inhibit cancer cell growth through the 
regulation of Wnt signaling (Figure 1). 
3.5. Isoflavone Induces Apoptosis through the Regulation of Notch Signaling 
The effects of isoflavone genistein on apoptosis through Notch signaling have been documented  
in several reports. We have found that isoflavone genistein inhibited Notch signaling, leading to   
the down-regulation of NF-κB activity, the induction of apoptosis and the inhibition of cell 
proliferation in pancreatic cancer cells [72]. Other investigators have also reported that isoflavone, 
genistein could inhibit the expression of Notch-1 and Notch-2 [114,116], which is consistent with our 
findings. These results suggest that isoflavone genistein could inhibit cancer cell growth and induce 
apoptosis through the inhibition of Notch signaling pathways (Figure 1), which is intimately linked 
with NF-κB signaling pathway. 
3.6. Isoflavone Induces Apoptosis through the Regulation of p53 Signaling 
To investigate the effects of isoflavone genistein on p53 pathway, we measured cell growth inhibition, 
apoptosis, and gene expression related to apoptosis in genistein treated H460 lung cancer cells, which 
harbor wild type p53, and H322 lung cancer cells that possess a mutation in the p53  
gene [95,117]. Isoflavone genistein inhibited both H460 and H322 cell growth in a dose dependent 
manner and induced apoptosis in both cell lines, suggesting that the effects of isoflavone genistein is 
independent of p53 status. The expression of Bax and p21
WAF1 was up-regulated in both H460 and H322 
cells treated with isoflavone genistein, which clearly suggest p53-independent pathway for the activation 
of apoptosis. Importantly, increased wild-type p53 protein was found in genistein-treated H460 cells, Nutrients 2011, 3  
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while no change in p53 expression was observed in H322 cells treated with isoflavone genistein. These 
results suggest that isoflavone genistein induces apoptosis in lung cancer cells through both   
p53-dependent and independent pathways. Isoflavone treatment also stabilized p53, leading to the 
inactivation of Bcl-2 and the induction of apoptosis in MCF-7 breast cancer cells [118]. Isoflavone 
genistein could also protect p53 wild type cells from toxicity and selectively increase apoptosis in  
p53-deficient cells [119]. Moreover, experimental studies have shown that isoflavone genistein 
treatment combined with sorafenib or perifosine could cause increased apoptosis and growth arrest 
through up-regulation of p53 and p21
WAF1 [120,121]. These findings suggest that isoflavone could 
induce apoptosis by up-regulation of p53 signaling (Figure 1); however, the role of p53 in the context 
of the biological activity of isofalvone has many layers of complexity. 
3.7. Isoflavone Induces Apoptosis through the Regulation of AR Signaling 
AR signaling is also a target of isoflavone genistein during the induction of apoptosis (Figure 1). 
We have reported that isoflavone genistein transcriptionally down-regulated AR, inhibited nuclear AR 
binding to androgen responsive element, and thereby decreased the transcription and protein 
expression of PSA in androgen-sensitive LNCaP cells, leading to the induction of apoptosis and the 
inhibition of cancer cell growth [122]. Similar findings has also been reported showing that isoflavone 
significantly down-regulated AR signaling with decreased AR protein levels and a consequent 
reduction in transcriptional activity and expression of PSA [123]. By mechanistic studies, we found 
that isoflavone-induced inhibition of cell proliferation and induction of apoptosis are partly mediated 
through the regulation of the Akt/FOXO3a/GSK-3β/AR signaling network [94]. The in vivo animal 
study also showed that dietary genistein down-regulated the expression of AR in the rat prostate at 
concentrations comparable to those found in humans on a soy diet [124]. Based on these results, we 
believe that the down-regulation of AR expression by isoflavone to induce apoptotic cell death could 
be an important strategy for the prevention and/or treatment of prostate cancer, especially castrate 
resistant prostate cancer for which there is no curative treatment. 
3.8. Isoflavone Regulates miRNAs, Leading to Increased Drug Sensitivity and Cancer Cell Death 
Emerging evidence has shown that natural agents including isoflavone could regulate the expression 
of specific miRNAs [125,126], which may increase sensitivity of cancer cells to conventional 
chemotherapeutics and, thereby, lead to increased cancer cell death induced by chemotherapeutics. 
Considering the non-toxic characteristics of isoflavone, targeting miRNAs by isoflavone combined with 
conventional chemotherapeutics could be a novel and safer approach for achieving better treatment 
outcome of patients diagnosed with cancers. It is well known that the aggressiveness of pancreatic cancer 
is in part due to its drug resistance characteristics, which are associated with pancreatic cancer stem-like 
cells and the acquisition of EMT phenotype. Therefore, we investigated the regulatory effects of 
isoflavone on miRNAs in pancreatic cancer cells that are gemcitabine-resistant and have the typical EMT 
phenotype that lost the expression of miR-200. We found that re-expression of miR-200 by pre-miR-200 
transfection or treatment of gemcitabine-resistant cells with isoflavone could cause up-regulation in the 
expression of miR-200, resulting in the down-regulation of ZEB1, slug, and vimentin, which were 
consistent with morphologic reversal of EMT phenotype leading to epithelial morphology [125]. Nutrients 2011, 3  
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Importantly, we found that miR-200 re-expression or isoflavone treatment increased sensitivity of 
gemcitabine-resistant pancreatic cells to gemcitabine, leading to increased pancreatic cancer cell death 
induced by gemcitabine [125]. These results suggest that miR-200 re-expression or isoflavone 
treatment could partially increase the sensitivity of gemcitabine-resistant cells to gemcitabine possibly 
through miR-200 mediated reversal of EMT status. A recent study has also shown that isoflavone, 
genistein could down-regulate miR-221/222, leading to the up-regulation of ARHI, one of the tumor 
suppressors, causing induction of apoptosis [127]. Therefore, conventional chemotherapeutics 
combined with isoflavone could be a novel strategy for achieving better treatment outcome of patients 
diagnosed with pancreatic and other cancers for which future in-depth mechanistic and clinical studies 
are warranted. 
4. Summary and Perspectives 
The data from in vivo human and animal studies and in vitro experiments clearly suggest that 
isoflavone exerts its inhibitory effects on carcinogenesis and cancer progression by induction of 
apoptosis and inhibition of cell proliferation. The induction of apoptosis by isoflavone has been 
believed to be mediated through the regulation of multiple cell signaling pathways including NF-κB, 
Akt, MAPK, Wnt, Notch, p53, and AR signaling pathways. Because of the complex communication 
between cell signaling networks, cancer cells always show alterations in multiple cellular signaling 
pathways. Therefore, regulation of multiple cell signaling pathways for controlling the behavior of 
cancer cells such as apoptosis requires agents that could target multiple pathways. It has now been well 
recognized that isoflavone could target multiple pathways to induce apoptotic cell death; therefore, we 
believe that isoflavone could be useful either alone or in combination with conventional therapeutics 
(chemotherapy and radiotherapy) for the prevention of tumor progression and/or treatment of most 
human malignancies. A number of phase I and II clinical trials have been conducted to investigate the 
toxicity and effects of isoflavones in healthy men and in patients with prostate cancer [128]. The results 
demonstrated that isoflavones could be administrated safely and that isoflavones were able to alter 
markers of cancer cell proliferation such as serum PSA and free testosterone in a larger number of 
subjects. Currently, several clinical trials are being conducted using isoflavone genistein, formulated 
genistein, or isoflavone analogue phenoxodiol in combination with IL-2, gemcitabine, docetaxel or 
cisplatin in the treatment of melanoma, kidney, ovarian and pancreatic cancers [128], suggesting the 
potential benefits of isoflavone in cancer in the clinical setting. However, further in-depth mechanistic 
studies in vitro, relevant animal model studies in vivo and novel clinical trials are needed in order to 
better understand the molecular mechanisms of isoflavone action, and to further realize the value of 
isoflavone and/or its synthetic analogs for the prevention of tumor progression and/or treatment of 
human malignancies. 
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